$ORGO
Organogenesis Holdings Inc. Stock $orgo

$orgo Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000119312519078332 Filed on March 18, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018 Q3
Revenue	$57.12M	$63.60M	$50.77M
YoY Change	60.78%	19.68%	-1.34%
Cost Of Revenue	$16.98M	$17.51M	$19.48M
YoY Change	16.93%	6.63%	21.07%
Gross Profit	$40.14M	$46.09M	$31.29M
YoY Change	91.08%	25.51%	-11.53%
Gross Profit Margin	70.27%	72.47%	61.64%
Selling, General & Admin	$48.89M	$47.48M	$38.58M
YoY Change	28.11%	30.48%	8.19%
% of Gross Profit	121.8%	103.01%	123.3%
Research & Development	$3.371M	$3.091M	$2.779M
YoY Change	19.37%	13.02%	19.53%
% of Gross Profit	8.4%	6.71%	8.88%
Depreciation & Amortization	$902.0K	$6.980M	$861.0K
YoY Change	3.44%
% of Gross Profit	2.25%	15.14%	2.75%
Operating Expenses	$52.26M	$50.57M	$41.36M
YoY Change	27.51%	29.26%	8.88%
Operating Profit	-$12.12M	-$4.480M	-$10.07M
YoY Change	-39.34%	86.51%	284.94%
Interest Expense	$1.778M	$2.663M	$2.940M
YoY Change	-26.8%	16.64%	31.66%
% of Operating Profit
Other Income/Expense, Net	-$3.508M	-$4.773M	-$2.981M
YoY Change	41.51%	111.29%	8.8%
Pretax Income	-$15.63M	-$9.253M	-$13.05M
YoY Change	-30.41%	98.52%	143.67%
Income Tax	$37.00K	$2.000K	$27.00K
% Of Pretax Income
Net Earnings	-$15.67M	-$9.255M	-$13.08M
YoY Change	-30.34%	109.01%	142.05%
Net Earnings / Revenue	-27.43%	-14.55%	-25.76%
Basic Earnings Per Share
Diluted Earnings Per Share	-$173.3K	-$280.6K	$494.9K
COMMON SHARES
Basic Shares Outstanding	92.01M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.60M	$21.30M	$0.00
YoY Change	30500.0%	21200.0%	-100.0%
Cash & Equivalents	$30.66M	$21.41M	$25.89M
Short-Term Investments
Other Short-Term Assets	$4.000M	$2.400M	$0.00
YoY Change	1900.0%	1100.0%	-100.0%
Inventory	$17.97M	$13.32M
Prepaid Expenses		$2.328M
Receivables	$32.51M	$34.08M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$85.06M	$71.13M	$0.00
YoY Change	28254.0%	43.01%	-100.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.45M	$39.62M
YoY Change		-5.91%
Goodwill	$25.54M	$25.54M
YoY Change		0.0%
Intangibles	$24.59M	$26.09M
YoY Change		-12.33%
Long-Term Investments
YoY Change
Other Assets	$1.072M	$579.0K	$316.3M
YoY Change	-99.66%	-21.22%	1.48%
Total Long-Term Assets	$91.39M	$92.55M	$316.3M
YoY Change	-70.85%	-6.5%	1.48%
TOTAL ASSETS
Total Short-Term Assets	$85.06M	$71.13M	$0.00
Total Long-Term Assets	$91.39M	$92.55M	$316.3M
Total Assets	$176.5M	$163.7M	$316.3M
YoY Change	-43.77%	10.06%	1.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.58M	$19.17M
YoY Change		0.59%
Accrued Expenses	$20.40M	$20.39M	$7.300M
YoY Change	324.9%	-9.59%	170.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$2.500M	$700.0K
YoY Change	-100.0%	2400.0%
Long-Term Debt Due	$2.300M	$7.500M
YoY Change
Total Short-Term Liabilities	$52.31M	$56.10M	$8.000M
YoY Change	925.63%	7.93%	196.3%
LONG-TERM LIABILITIES
Long-Term Debt	$39.64M	$49.20M	$0.00
YoY Change
Other Long-Term Liabilities	$5.680M	$5.931M	$5.100M
YoY Change	-47.89%	288.66%	-53.21%
Total Long-Term Liabilities	$45.32M	$5.931M	$5.100M
YoY Change	315.73%	288.66%	-53.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$52.31M	$56.10M	$8.000M
Total Long-Term Liabilities	$45.32M	$5.931M	$5.100M
Total Liabilities	$143.9M	$116.6M	$13.10M
YoY Change	804.99%	-25.84%	-2.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$145.6M	-$130.2M
YoY Change		99.12%
Common Stock	$178.1M	$177.3M
YoY Change		253.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	$728.5K
Shareholders Equity	$32.56M	$47.04M	-$24.23M
YoY Change
Total Liabilities & Shareholders Equity	$176.5M	$163.7M	$316.3M
YoY Change	-43.77%	10.06%	1.35%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	-$15.67M	-$9.255M	-$13.08M
YoY Change	-30.34%	109.01%	142.05%
Depreciation, Depletion And Amortization	$902.0K	$6.980M	$861.0K
YoY Change	3.44%
Cash From Operating Activities	-$9.558M	-$60.02M	-$280.0K
YoY Change	114.45%	59920.0%	-48.15%
INVESTING ACTIVITIES
Capital Expenditures	$317.0K	-$1.860M
YoY Change	387.69%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities	-$317.0K	-$1.860M
YoY Change	387.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$46.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	19.13M	81.04M	220.0K
YoY Change	520.8%	80940.0%
NET CHANGE
Cash From Operating Activities	-9.558M	-60.02M	-280.0K
Cash From Investing Activities	-317.0K	-1.860M
Cash From Financing Activities	19.13M	81.04M	220.0K
Net Change In Cash	9.258M	19.16M	-60.00K
YoY Change	-742.92%		-88.89%
FREE CASH FLOW
Cash From Operating Activities	-$9.558M	-$60.02M	-$280.0K
Capital Expenditures	$317.0K	-$1.860M
Free Cash Flow	-$9.875M	-$58.16M
YoY Change	118.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018Q4	orgo	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	25415000
CY2017Q4	orgo	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	22551000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	66388000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51973000
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	177272000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	50086000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-130240000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65409000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	47041000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-15317000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	163678000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	148722000
CY2018	us-gaap	Revenues Revenues	193449000
CY2017	us-gaap	Revenues Revenues	198508000
CY2016	us-gaap	Revenues Revenues	138732000
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	68808000
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	61220000
CY2016	us-gaap	Cost Of Revenue CostOfRevenue	48201000
CY2018	us-gaap	Gross Profit GrossProfit	124641000
CY2017	us-gaap	Gross Profit GrossProfit	137288000
CY2016	us-gaap	Gross Profit GrossProfit	90531000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	161961000
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	133717000
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	93029000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10742000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9065000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6277000
CY2018	orgo	Write Off Of Deferred Offering Costs WriteOffOfDeferredOfferingCosts	3494000
CY2017	orgo	Write Off Of Deferred Offering Costs WriteOffOfDeferredOfferingCosts
CY2016	orgo	Write Off Of Deferred Offering Costs WriteOffOfDeferredOfferingCosts
CY2018	us-gaap	Operating Expenses OperatingExpenses	176197000
CY2017	us-gaap	Operating Expenses OperatingExpenses	142782000
CY2016	us-gaap	Operating Expenses OperatingExpenses	99306000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-51556000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-5494000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-8775000
CY2018	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	469000
CY2017	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	1037000
CY2016	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	737000
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2095000
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	162000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-64831000
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	863000
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2221000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-16987000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	285000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13191000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9056000
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5926000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-8388000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64747000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14550000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14701000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7025000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest
CY2018Q4	orgo	Working Capital WorkingCapital	4743000
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69318456
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63876767
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63196067
CY2018	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-91730000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-119000
CY2018	orgo	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	-2707000
CY2018	orgo	Stock Issued During Period Value Extinguishment Of Debt StockIssuedDuringPeriodValueExtinguishmentOfDebt	-42764000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	-1075000
CY2018	orgo	Offering Costs OfferingCosts	270000
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported results of operations during the reporting period. Actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4	orgo	Redeemable Common Stock Liability RedeemableCommonStockLiability	6762000
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2545000
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	7501000
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	5369000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19165000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19053000
CY2018Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	26484000
CY2017Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	17618000
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	12578000
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14816000
CY2017Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	52142000
CY2017Q4	us-gaap	Due To Affiliate Noncurrent DueToAffiliateNoncurrent	4500000
CY2017Q4	orgo	Warrant Liability WarrantLiability	2238000
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	130000
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	74000
CY2018Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	10154000
CY2017Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	12390000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	903000
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1526000
CY2018Q4	us-gaap	Liabilities Liabilities	116637000
CY2017Q4	us-gaap	Liabilities Liabilities	157277000
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	6762000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	9000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2018Q4	us-gaap	Cash Cash	21291000
CY2017Q4	us-gaap	Cash Cash	2309000
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	114000
CY2017Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	49000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34077000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28124000
CY2018Q4	us-gaap	Inventory Net InventoryNet	13321000
CY2017Q4	us-gaap	Inventory Net InventoryNet	14270000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2328000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4399000
CY2017Q4	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	589000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	71131000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	49740000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39623000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42112000
CY2018Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	477000
CY2017Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	413000
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26091000
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29759000
CY2018Q4	us-gaap	Goodwill Goodwill	25539000
CY2017Q4	us-gaap	Goodwill Goodwill	25539000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	238000
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	424000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	579000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	735000
CY2018Q4	us-gaap	Assets Assets	163678000
CY2017Q4	us-gaap	Assets Assets	148722000
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	81200000
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91261412
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family: "times new roman", serif; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; font-size: 10pt;"> </div><div style="font-family: "times new roman", serif; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Nature of Business</div></div></div></div> <div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Organogenesis Holdings Inc. (formerly Avista Healthcare Public Acquisition Corp.) (“ORGO” or the “Company”) is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. The Company’s products have been shown through clinical and scientific studies to support and, in some cases, accelerate tissue healing and improve patient outcomes. The Company is advancing the standard of care in each phase of the healing process through multiple breakthroughs in tissue engineering and cell therapy. The Company’s solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease and smoking. The Company offers differentiated products and in-house customer support to a wide range of health care customers including hospitals, wound care centers, government facilities, ambulatory service centers (ASCs) and physician offices. The Company’s mission is to provide integrated healing solutions that substantially improve medical outcomes and the lives of patients while lowering the overall cost of care. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;">The Company offers a comprehensive portfolio of products in the markets it serves that address patient needs across the continuum of care. The Company has and intends to continue to generate data from clinical trials, real world outcomes and health economics research that validate the clinical efficacy and value proposition offered by the Company’s products. The majority of the existing and pipeline products in the Company’s portfolio have Premarket Application approval, Business License Applicant approval or Premarket Notification 510(k) clearance from the United States Food and Drug Administration (“FDA”). Given the extensive time and cost required to conduct clinical trials and receive FDA approvals, the Company believes its data and regulatory approvals provide us a strong competitive advantage. The Company’s product development expertise and multiple technology platforms provide a robust product pipeline which the Company believes will drive future growth.<div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 18pt; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Merger with Avista Healthcare Public Acquisition Corp </div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; margin-right: 0px; text-indent: 0.79in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On December 10, 2018, Avista Healthcare Public Acquisition Corp., our predecessor company (“AHPAC”), consummated the previously announced merger (the “Avista Merger”) pursuant to an Agreement and Plan of Merger, dated as of August 17, 2018 (as amended, the “Avista Merger Agreement”), by and among AHPAC, Avista Healthcare Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of AHPAC (“Avista Merger Sub”) and Organogenesis Inc., a Delaware corporation (“Organogenesis Inc.”). </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As a result of the Avista Merger and the other transactions contemplated by the Avista Merger Agreement, Avista Merger Sub merged with and into Organogenesis Inc., with Organogenesis Inc. surviving the Avista Merger and becoming a wholly owned subsidiary of AHPAC. In addition, in connection with the Avista Merger, and in accordance with Section 388 of the Delaware General Corporation Law and the Cayman Islands Companies Law (2018 Revision), AHPAC redomesticated as a Delaware corporation (the “Domestication”). After the Domestication, AHPAC changed its name to Organogenesis Holdings Inc. (ORGO). </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the terms of the Avista Merger Agreement, at the effective time of the Avista Merger, each share of Organogenesis Inc. common stock then issued and outstanding was automatically cancelled, extinguished and converted into the right to receive 2.03 shares of ORGO Class A common stock, par value $0.0001 per share, (after giving effect to the Domestication). At the effective time of the Avista Merger, 75,073,548 shares of ORGO Class A common stock were issued to the equity holders of Organogenesis Inc. In addition, all outstanding options and warrants (other than warrants that expired, were exercised or were deemed automatically net exercised immediately prior to the Avista Merger) exercisable for common stock in Organogenesis Inc. were exchanged for options and warrants exercisable for ORGO Class A common stock </div>with the same terms and conditions except adjusted by the aforementioned exchange ratio<div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Avista Merger was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States (“GAAP”). Under this method of accounting, AHPAC was treated as the “acquired” company for accounting purposes. This determination was primarily based on Organogenesis Inc.’s equity holders having a majority of the voting power of the combined company, Organogenesis Inc. comprising the ongoing operations of the combined entity, Organogenesis Inc. comprising a majority of the governing body of the combined company, and the Organogenesis Inc.’s senior management comprising the senior management of the combined company. Accordingly, for accounting purposes, the Avista Merger was treated as the equivalent of Organogenesis Inc. issuing stock for the net assets of AHPAC, accompanied by a recapitalization. The net assets of AHPAC were recorded at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Avista Merger are those of Organogenesis Inc. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Prior to the completion of the Avista Merger, on August 17, 2018, the PIPE investors also purchased, 6,538,732 shares of ORGO Class A common stock for an aggregate purchase price of $46,000 (the “Initial Avista Investment”). The Company received the proceeds from the Initial Avista Investment in August 2018.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;">Concurrently with the completion of the Avista Merger, Avista Capital Partners IV, L.P. and Avista Capital Partners IV (Offshore), L.P. (the “PIPE Investors”) purchased 9,022,741 shares of ORGO Class A common stock and 4,100,000 warrants to purchase one-half of one share of ORGO Class A common stock for an aggregate purchase price of $46,000 (the “Additional Avista Investment”). The Company received the proceeds from the Additional Avista Investment in December 2018.</div><div style="font-family: "times new roman", serif; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px; font-size: 13.3333px;">Concurrently with the signing of the Avista Merger Agreement, Organogenesis Inc.’s lenders agreed to release the subordination on the affiliate debt and the affiliate guarantee on the term debt, and the holders of the affiliate debt executed and delivered to the Company an exchange agreement whereby such creditors and the Company agreed that, concurrently with the consummation of the Avista Merger, outstanding principal of<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> $</div></div><div style="font-family: "times new roman", serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45,</div></div><div style="font-family: "times new roman", serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">746</div></div>, with a carrying value of $40,669, related to the affiliate debt was exchanged for <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">6</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">,502,679 </div></div>shares of ORGO Class A common stock and a cash payment of <div style="font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: "times new roman", serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt; background: none; text-decoration: none;;display:inline;">$</div></div><div style="font-family: "times new roman", serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35,641</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, representing $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22,000</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of principal and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13,641</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: "times new roman", serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div>of accrued interest related to all aforementioned affiliate debt and accrued affiliate loan fees as of and through the closing date of the Avista Merger. Following the consummation of these transactions, the affiliate debt was deemed fully paid and satisfied in full and was discharged and terminated.<div style="font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: "times new roman", serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 18pt; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Acquisition of Nutech Medical, Inc. </div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In March 2017, the Company purchased Nutech Medical, Inc. (“NuTech Medical”) pursuant to an Agreement of Plan of Merger (“NuTech Merger Agreement”) dated <div style="letter-spacing: 0px; top: 0px;;display:inline;">March 18, 2017</div>. As a result of this transaction, NuTech Medical merged with and into Prime Merger Sub, LLC, with Prime Merger Sub, LLC surviving the merger as a wholly-owned subsidiary of the Company. Under the terms of the NuTech Merger Agreement, the Company transferred $12,000 in cash, $7,500 of deferred acquisition consideration, 137,543 fully vested common stock options and 3,642,746 shares of the Company’s common stock, of which 728,549 shares are redeemable. Results of operations for NuTech Medical are included in the Company’s consolidated financial statements from the date of acquisition (See Note 5). </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 18pt; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Going Concern </div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Through December 31, 2018, the Company has funded its operations primarily with cash flow from product sales and proceeds from loans from affiliates and entities controlled by its affiliates, sales of its common stock and third-party debt. The Company has incurred recurring losses since inception, including net losses of $64,831, $8,388, and $16,987 for the years ended December 31, 2018, 2017 and 2016, respectively. In addition, as of December 31, 2018, the Company had an accumulated deficit of $130,240 and working capital of $4,743. The Company expects to continue to generate operating losses for the foreseeable future. As of March 18, 2019, the issuance date of the consolidated financial statements for the year ended December 31, 2018, the Company expects that its cash of $21,291 as of </div>December 31, 2018, plus cash flows from product sales, availability under the New Credit Agreement (see Note 28) with Silicon Valley Bank, which was entered into in March 2019, will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least March 31, 2020.<div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 1pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none; text-indent: 0.79in;"><div style="font-family: "times new roman", serif; font-size: 1pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px; line-height: 12pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company may seek to raise additional funding through public and/or private equity financings, debt financings or other strategic transactions. The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to continue investing in product development, sales and marketing and customer support for its products. The long-term continuation of the Company’s business plan is dependent upon the generation of sufficient revenues from its products to offset expenses, capital expenditures, debt service payments, and contingent payment obligations. In the event that the Company does not generate sufficient revenues and is unable to obtain funding, the Company will be forced to delay, reduce, or eliminate some or all of its research and development programs, product portfolio expansion, commercialization efforts or capital expenditures, which could adversely affect the Company’s business prospects, ability to meet long-term liquidity needs or the Company may be unable to continue operations. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px; line-height: 12pt;"> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2017Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2724000
CY2018	orgo	Write Off Of Deferred Offering Cost WriteOffOfDeferredOfferingCost	3494000
CY2018Q4	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	0
CY2017Q4	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	57322000
CY2018	orgo	Long Term Debt Due To Affiliates Fair Value LongTermDebtDueToAffiliatesFairValue	0
CY2017	orgo	Long Term Debt Due To Affiliates Fair Value LongTermDebtDueToAffiliatesFairValue	35161000
CY2018	orgo	Excise Tax Percent ExciseTaxPercent	0.023
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	270000
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1883000
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1006000
CY2018	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	0.03
CY2018Q4	us-gaap	Variable Interest Entity Nonconsolidated Carrying Amount Assets And Liabilities Net VariableInterestEntityNonconsolidatedCarryingAmountAssetsAndLiabilitiesNet	4665000
CY2018Q4	orgo	Variable Interest Entity Nonconsolidated Accumulated Deficit VariableInterestEntityNonconsolidatedAccumulatedDeficit	3297000
CY2018Q4	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	7962000
CY2018Q4	us-gaap	Variable Interest Entity Nonconsolidated Carrying Amount Liabilities VariableInterestEntityNonconsolidatedCarryingAmountLiabilities	18939000
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1554000
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1764000
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2451000
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	2834000
CY2017	us-gaap	Operating Lease Expense OperatingLeaseExpense	2276000
CY2016	us-gaap	Operating Lease Expense OperatingLeaseExpense	1735000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4530000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3937000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3209000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	446000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	12122000
CY2018Q4	orgo	Accrued Legal Expenses AccruedLegalExpenses	1000000
CY2017Q4	orgo	Accrued Legal Expenses AccruedLegalExpenses	1000000
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	5000000
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	5000000
CY2017Q1	orgo	Business Combination Contingent Consideration Liability Interest Rate BusinessCombinationContingentConsiderationLiabilityInterestRate	0.06
CY2017Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Reasons BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons	There was a $500 reduction to the purchase price due to changes in the amount of working capital acquired.
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Method FiniteLivedIntangibleAssetsAmortizationMethod	accelerated methods
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66983138
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25727964
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9440248
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6716355
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91261412
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66983138
CY2018Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	37497000
CY2017Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	31349000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3420000
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3225000
CY2017	orgo	Allowance For Doubtful Accounts Receivable Write Offs1 AllowanceForDoubtfulAccountsReceivableWriteOffs1	-50000
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3225000
CY2018	orgo	Allowance For Doubtful Accounts Receivable Write Offs1 AllowanceForDoubtfulAccountsReceivableWriteOffs1	-962000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3420000
CY2018	us-gaap	Interest Expense InterestExpense	10853000
CY2017	us-gaap	Interest Expense InterestExpense	8139000
CY2016	us-gaap	Interest Expense InterestExpense	5627000
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	64000
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	129000
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	153000
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4711000
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6537000
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1759000
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	991000
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6851000
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6742000
CY2018	orgo	Inventory Reserve Charged To Cost Of Goods Sold InventoryReserveChargedToCostOfGoodsSold	5949000
CY2017	orgo	Inventory Reserve Charged To Cost Of Goods Sold InventoryReserveChargedToCostOfGoodsSold	5497000
CY2016	orgo	Inventory Reserve Charged To Cost Of Goods Sold InventoryReserveChargedToCostOfGoodsSold	7472000
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2951000
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2954000
CY2018Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure
CY2017Q4	us-gaap	Prepaid Rent PrepaidRent	29000
CY2018Q4	orgo	Prepaid Subscription PrepaidSubscription	594000
CY2017Q4	orgo	Prepaid Subscription PrepaidSubscription	584000
CY2018Q4	us-gaap	Supplies Supplies	116000
CY2017Q4	us-gaap	Supplies Supplies	36000
CY2018Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	392000
CY2017Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	588000
CY2018Q4	us-gaap	Prepaid Insurance PrepaidInsurance	223000
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	196000
CY2018Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	764000
CY2018Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	239000
CY2017Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	242000
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2328000
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4399000
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	589000
CY2017Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	2238000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-212000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	101000
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	214000
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	65000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	9000
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	62000
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-102000
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	276000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	65000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	212000
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6401000
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-900000
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-26000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4174000
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3950000
CY2018Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1000000
CY2017Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1000000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.39
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.62
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15218000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11826000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	309000
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	539000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7025000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	79097000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	78518000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	62435000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	59212000
CY2017	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	418000
CY2017	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1	418000
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	8000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	34707000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	26725000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	3208000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1327000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	26000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	101000
CY2018Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	12219000
CY2017Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	8706000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	29000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	293000
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	2765000
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	3757000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47424000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	33395000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47186000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32971000
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2463000
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3610000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25415000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22551000
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	963000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1070000
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1733000
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M7D
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.184
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	1.475
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.309
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.039
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.030
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.036
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.035
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	5.99
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3.45
CY2018Q4	orgo	Fair Value Of Common Share FairValueOfCommonShare	5.82
CY2017Q4	orgo	Fair Value Of Common Share FairValueOfCommonShare	3.45
CY2017	orgo	Effective Income Tax Rate Reconciliation Tax Reform Act EffectiveIncomeTaxRateReconciliationTaxReformAct	-1.344
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7150214
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.023
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.025
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.023
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.068
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.032
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.022
CY2018	orgo	Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves	-0.001
CY2017	orgo	Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves	-0.005
CY2016	orgo	Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves	-0.002
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.483
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2018Q4	orgo	Number Of Shares Issues As Collateral For Secured Debt NumberOfSharesIssuesAsCollateralForSecuredDebt	675990
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3486000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3663000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3417000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	157000
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	231000
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	325000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	357000
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	408000
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	79000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3286000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0273
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0205
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M20D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.420
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.457
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.77
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P6Y8M12D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	248567
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.99
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	76664
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.55
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	55402
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7266715
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.91
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P6Y6M
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.53
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M16D
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	27280000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6948699
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.82
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y9M4D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	33096000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5396880
CY2018	orgo	Changes In Fair Value Of Underlying Shares Percentage ChangesInFairValueOfUnderlyingSharesPercentage	0.1
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	9573000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	4308000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	4308000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	4737000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Net Minimum Payments1 CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1	22926000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	5271000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	17655000
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	7501000
CY2018Q4	us-gaap	Line Of Credit LineOfCredit	26484000
CY2017Q4	us-gaap	Line Of Credit LineOfCredit	17618000
CY2018Q4	us-gaap	Notes Payable NotesPayable	15885000
CY2017Q4	us-gaap	Notes Payable NotesPayable	15895000
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	762000
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	1079000
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0
CY2018Q4	orgo	Notes Payable Due In Next Twelve Month NotesPayableDueInNextTwelveMonth	2211000
CY2018Q4	orgo	Notes Payable Due In Two Years NotesPayableDueInTwoYears	4646000
CY2018Q4	orgo	Notes Payable Due In Three Years NotesPayableDueInThreeYears	5384000
CY2018Q4	orgo	Notes Payable Due In Four Years NotesPayableDueInFourYears	3644000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	36580000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10489000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	36580000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6821000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	29759000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5993000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3192000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3257000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3247000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3283000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	7119000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	26091000
CY2018	orgo	Other Assets Amortized Value OtherAssetsAmortizedValue	702000
CY2018Q2	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	5000000
CY2018Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent
CY2017Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	9241000
CY2018Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	57487000
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5345000
CY2018Q4	us-gaap	Long Term Debt LongTermDebt
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	52142000
CY2018Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent
CY2017Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	4500000
CY2018Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	46000000
CY2018Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	6502679
CY2018Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	5000000
CY2018Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	243000
CY2017Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	145000
CY2018Q4	us-gaap	Other Assets OtherAssets	318000
CY2015Q3	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	375000
CY2017Q2	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	2250000
CY2017Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	2512000
CY2017Q1	orgo	Put Options Exercise Price At Closing PutOptionsExercisePriceAtClosing	9.28
CY2017Q1	orgo	Put Options Exercise Price Prior To Second Aniversary PutOptionsExercisePricePriorToSecondAniversary	9.28
CY2017	orgo	Accrued Interest Notes Receivable AccruedInterestNotesReceivable	111000
CY2017	orgo	Impairment On Notes Receivable ImpairmentOnNotesReceivable	113000
CY2018	orgo	Accrued Interest Notes Receivable AccruedInterestNotesReceivable	64000
CY2017Q1	orgo	Interest Rate On The Un Paid Fee InterestRateOnTheUnPaidFee	0.15
CY2016	orgo	Accrued Interest Notes Receivable AccruedInterestNotesReceivable	108000
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	209000
CY2017	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	159000
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2018Q4	us-gaap	Secured Debt SecuredDebt	635000
CY2017Q4	us-gaap	Secured Debt SecuredDebt	635000
CY2018Q4	us-gaap	Interest Receivable InterestReceivable	2937000
CY2018	orgo	Bonus Payment BonusPayment	904000
CY2018	orgo	Deemed Uncollectible Loan DeemedUncollectibleLoan	0
CY2017	orgo	Impairment Of Employer Loan ImpairmentOfEmployerLoan	113000
CY2017Q4	us-gaap	Interest Receivable InterestReceivable	3873000
CY2018	orgo	Impairment Of Employer Loan ImpairmentOfEmployerLoan	0
CY2017	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	19761000
CY2018Q4	orgo	Operating Loss Carryforwards Tax Credit Research OperatingLossCarryforwardsTaxCreditResearch	878000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47186000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32971000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14215000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax	238000
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3722000
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3801000
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3802000
CY2018	orgo	Description Of Recognized Tax Benefits Upon Ultimate Settlement DescriptionOfRecognizedTaxBenefitsUponUltimateSettlement	The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.
CY2018Q4	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2021-04-30
CY2018Q4	orgo	Business Combination Contingent Consideration Quarterly Payments BusinessCombinationContingentConsiderationQuarterlyPayments	1000000
CY2018Q4	orgo	Business Combination Contingent Consideration Final Payment BusinessCombinationContingentConsiderationFinalPayment	4000000
CY2018	orgo	Variable Interest Entity Nonconsolidated Consideration Transferred VariableInterestEntityNonconsolidatedConsiderationTransferred
CY2018	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount
CY2018Q4	orgo	Deferred Tax Asset Reclassified Alternative Minimum Tax Percentage DeferredTaxAssetReclassifiedAlternativeMinimumTaxPercentage	0.5
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	24581000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33976000
CY2019Q1	orgo	Line Of Credit Facility Termination Fee Amount LineOfCreditFacilityTerminationFeeAmount	0
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1633000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1308000
CY2018Q4	orgo	Business Combination Contingent Consideration Liability Accrued Interest BusinessCombinationContingentConsiderationLiabilityAccruedInterest	618000
CY2017Q4	us-gaap	Debt Instrument Collateral Amount DebtInstrumentCollateralAmount	3646000
CY2018Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	728549
CY2017Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	728549
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	728549
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	728549
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.94
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	3514000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	-473000
CY2016	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	5200000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-15979000
CY2017	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10270000
CY2017	us-gaap	Stockholders Equity Other StockholdersEquityOther	-9336000
CY2017	orgo	Adjustments To Additional Paid In Capital Extinguishment Of Debt AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfDebt	4577000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-221000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	959000
CY2017	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	1000000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	-919000
CY2017	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	423000
CY2018	orgo	Adjustments To Additional Paid In Capital Recapitalization Cost AdjustmentsToAdditionalPaidInCapitalRecapitalizationCost	-11206000
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2500000
CY2018	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	1309000
CY2018	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1	99000
CY2017Q4	orgo	Business Combination Contingent Consideration Liability Accrued Interest BusinessCombinationContingentConsiderationLiabilityAccruedInterest	318000
CY2017Q4	us-gaap	Other Assets OtherAssets	463000
CY2018	us-gaap	Debt Instrument Covenant Description DebtInstrumentCovenantDescription	maintain Minimum Liquidity (as defined in the New Credit Agreement) equal to the greater of (i) 6 months Monthly Burn (as defined in the New Credit Agreement) and (ii) $10,000.
CY2017Q1	orgo	Put Option Shares Back Price PutOptionSharesBackPrice	9.28
CY2018	us-gaap	Accretion Expense AccretionExpense	0
CY2017	us-gaap	Accretion Expense AccretionExpense	423000
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46000000
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	270000
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	17732700
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1561485
CY2017	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	423000
CY2018	orgo	Net Income Loss Attribute To Parent NetIncomeLossAttributeToParent	-64831000
CY2017	orgo	Net Income Loss Attribute To Parent NetIncomeLossAttributeToParent	-8811000
CY2016	orgo	Net Income Loss Attribute To Parent NetIncomeLossAttributeToParent	-16987000
CY2018Q1	us-gaap	Revenues Revenues	35529000
CY2018Q2	us-gaap	Revenues Revenues	43552000
CY2018Q3	us-gaap	Revenues Revenues	50769000
CY2018Q4	us-gaap	Revenues Revenues	63599000
CY2018Q1	us-gaap	Cost Of Revenue CostOfRevenue	14521000
CY2018Q2	us-gaap	Cost Of Revenue CostOfRevenue	17300000
CY2018Q3	us-gaap	Cost Of Revenue CostOfRevenue	19477000
CY2018Q4	us-gaap	Cost Of Revenue CostOfRevenue	17510000
CY2018Q1	us-gaap	Gross Profit GrossProfit	21008000
CY2018Q2	us-gaap	Gross Profit GrossProfit	26252000
CY2018Q3	us-gaap	Gross Profit GrossProfit	31292000
CY2018Q4	us-gaap	Gross Profit GrossProfit	46089000
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38165000
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37735000
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38583000
CY2018Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	47478000
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2824000
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2048000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2779000
CY2018Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3091000
CY2018Q2	orgo	Write Off Of Deferred Offering Costs WriteOffOfDeferredOfferingCosts	3494000
CY2018Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	40989000
CY2018Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	43277000
CY2018Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	41362000
CY2018Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	50569000
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19981000
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17025000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10070000
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4480000
CY2018Q1	us-gaap	Interest Expense InterestExpense	2429000
CY2018Q2	us-gaap	Interest Expense InterestExpense	2801000
CY2018Q3	us-gaap	Interest Expense InterestExpense	2960000
CY2018Q4	us-gaap	Interest Expense InterestExpense	2663000
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	19000
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	20000
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	20000
CY2018Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000
CY2018Q1	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	74000
CY2018Q2	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	175000
CY2018Q3	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	50000
CY2018Q4	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	170000
CY2018Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2095000
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9000
CY2018Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	150000
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2479000
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2958000
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2981000
CY2018Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4773000
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22460000
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19983000
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13051000
CY2018Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9253000
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	28000
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27000
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27000
CY2018Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-22488000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-20010000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-13078000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-9255000
CY2018Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest
CY2018Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest
CY2018Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest
CY2018Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-22488000
CY2018Q2	us-gaap	Profit Loss ProfitLoss	-20010000
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-13078000
CY2018Q4	us-gaap	Profit Loss ProfitLoss	-9255000
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64320931
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66361998
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69496279
CY2018Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	76952174
CY2017Q1	us-gaap	Revenues Revenues	39837000
CY2017Q2	us-gaap	Revenues Revenues	54071000
CY2017Q3	us-gaap	Revenues Revenues	51458000
CY2017Q4	us-gaap	Revenues Revenues	53142000
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	13305000
CY2017Q2	us-gaap	Cost Of Revenue CostOfRevenue	15406000
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	16087000
CY2017Q4	us-gaap	Cost Of Revenue CostOfRevenue	16422000
CY2017Q1	us-gaap	Gross Profit GrossProfit	26532000
CY2017Q2	us-gaap	Gross Profit GrossProfit	38665000
CY2017Q3	us-gaap	Gross Profit GrossProfit	35371000
CY2017Q4	us-gaap	Gross Profit GrossProfit	36720000
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27952000
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33716000
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35662000
CY2017Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36387000
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1551000
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2454000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2325000
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2735000
CY2017Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	29503000
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	590000
CY2017Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	36170000
CY2017Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	37987000
CY2017Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	39122000
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2971000
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	2495000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2616000
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2402000
CY2017Q1	us-gaap	Interest Expense InterestExpense	1592000
CY2017Q2	us-gaap	Interest Expense InterestExpense	2031000
CY2017Q3	us-gaap	Interest Expense InterestExpense	2233000
CY2017Q4	us-gaap	Interest Expense InterestExpense	2283000
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	38000
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	35000
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	28000
CY2017Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	28000
CY2017Q1	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	-55000
CY2017Q2	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	505000
CY2017Q3	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	534000
CY2017Q4	orgo	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	53000
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	62000
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-119000
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000
CY2017Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	49000
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1437000
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2620000
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2740000
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2259000
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4408000
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-125000
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5356000
CY2017Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4661000
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6683000
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-156000
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	47000
CY2017Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-233000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	2275000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	31000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5403000
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-4428000
CY2017Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	273000
CY2017Q1	us-gaap	Profit Loss ProfitLoss	1685000
CY2017Q2	us-gaap	Profit Loss ProfitLoss	-242000
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-5403000
CY2017Q4	us-gaap	Profit Loss ProfitLoss	-4428000
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63311814
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64022549
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1166000
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64040527
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64121501
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64022549
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64040527
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64121501
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	8000
CY2018Q4	us-gaap	Advances To Affiliate AdvancesToAffiliate	40669000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2109000
CY2018	us-gaap	Profit Loss ProfitLoss	-64831000
CY2017	us-gaap	Profit Loss ProfitLoss	-7525000
CY2016	us-gaap	Profit Loss ProfitLoss	-14766000
CY2018	us-gaap	Depreciation Depreciation	3309000
CY2017	us-gaap	Depreciation Depreciation	3591000
CY2016	us-gaap	Depreciation Depreciation	5702000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3669000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2037000
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1617000
CY2018	orgo	Non Cash Interest Expense NonCashInterestExpense	3300000
CY2017	orgo	Non Cash Interest Expense NonCashInterestExpense	2415000
CY2016	orgo	Non Cash Interest Expense NonCashInterestExpense	1662000
CY2018	orgo	Non Cash Interest Income NonCashInterestIncome	64000
CY2017	orgo	Non Cash Interest Income NonCashInterestIncome	111000
CY2016	orgo	Non Cash Interest Income NonCashInterestIncome	108000
CY2018	orgo	Non Cash Rent Expense Income NonCashRentExpenseIncome	56000
CY2017	orgo	Non Cash Rent Expense Income NonCashRentExpenseIncome	70000
CY2016	orgo	Non Cash Rent Expense Income NonCashRentExpenseIncome	-26000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	186000
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7301000
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1209000
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	9000
CY2017	orgo	Impairment Of Notes Receivable ImpairmentOfNotesReceivable	113000
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1157000
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25000
CY2018	orgo	Provision For Inventory Reserve ProvisionForInventoryReserve	5949000
CY2017	orgo	Provision For Inventory Reserve ProvisionForInventoryReserve	5497000
CY2016	orgo	Provision For Inventory Reserve ProvisionForInventoryReserve	7472000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	1075000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	919000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	473000
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	469000
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1037000
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	737000
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2095000
CY2017	orgo	Fair Value Adjustment Of Interest Rate Swap FairValueAdjustmentOfInterestRateSwap	6000
CY2016	orgo	Fair Value Adjustment Of Interest Rate Swap FairValueAdjustmentOfInterestRateSwap	-253000
CY2018	orgo	Fair Value Adjustment Of Forfeiture Rights FairValueAdjustmentOfForfeitureRights	589000
CY2017	orgo	Fair Value Adjustment Of Forfeiture Rights FairValueAdjustmentOfForfeitureRights	-212000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7110000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7010000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6556000
CY2018	orgo	Payment Of Recapitalization Cost PaymentOfRecapitalizationCost	-11206000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5000000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3817000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5367000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1414000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2680000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1009000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-60000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3967000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	33000
CY2018	orgo	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	368000
CY2017	orgo	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	982000
CY2016	orgo	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	1110000
CY2018	orgo	Increase Decrease In Accrued Interest Of Affiliate Debt IncreaseDecreaseInAccruedInterestOfAffiliateDebt	9241000
CY2017	orgo	Increase Decrease In Accrued Interest Of Affiliate Debt IncreaseDecreaseInAccruedInterestOfAffiliateDebt	-3190000
CY2016	orgo	Increase Decrease In Accrued Interest Of Affiliate Debt IncreaseDecreaseInAccruedInterestOfAffiliateDebt	-2339000
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	56000
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	100000
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	35000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60739000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3574000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4871000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1857000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2426000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1361000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	8000
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	115000
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	11790000
CY2017	orgo	Variable Interest Entity Deconsolidation VariableInterestEntityDeconsolidation	666000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1856000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14874000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1246000
CY2018	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	8866000
CY2017	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	12749000
CY2016	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-2399000
CY2017	orgo	Proceeds From Repayments Of Notes Payable To Related Parties ProceedsFromRepaymentsOfNotesPayableToRelatedParties	-1335000
CY2016	orgo	Proceeds From Repayments Of Notes Payable To Related Parties ProceedsFromRepaymentsOfNotesPayableToRelatedParties	2398000
CY2018	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	22680000
CY2016	orgo	Proceeds From Affiliates Long Term Debt ProceedsFromAffiliatesLongTermDebt	17204000
CY2018	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	92000000
CY2016Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	415000
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	270000
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10000
CY2017	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6325000
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5250000
CY2016	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	5200000
CY2017	orgo	Notes Payable Converted Warrants Issued NotesPayableConvertedWarrantsIssued	-959000
CY2017	orgo	Issue Of Contingent Consideration IssueOfContingentConsideration	-377000
CY2016	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	23000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	119000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	221000
CY2017	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	1000000
CY2017	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	16000000
CY2017	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	2500000
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	177000
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	862000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	81642000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18948000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6776000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19047000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	500000
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	659000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2358000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1858000
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1199000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21405000
CY2018	us-gaap	Interest Paid InterestPaid	7553000
CY2017	us-gaap	Interest Paid InterestPaid	5715000
CY2016	us-gaap	Interest Paid InterestPaid	3965000
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	8000
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	96000
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	29000
CY2018	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	42764000
CY2018	orgo	Non Cash Gain On Investor Debt Extinguishment NonCashGainOnInvestorDebtExtinguishment	-2707000
CY2018	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1000
CY2018	orgo	Exercise Of Put Option Redeemable Common Stock ExerciseOfPutOptionRedeemableCommonStock	-6762000
CY2016	orgo	Subordinated Notes Converted Warrants Issued SubordinatedNotesConvertedWarrantsIssued	-464000
CY2016	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	680000
CY2018	orgo	Non Cash Purchase Of Property Plant And Equipment NonCashPurchaseOfPropertyPlantAndEquipment	172000
CY2017	orgo	Non Cash Purchase Of Property Plant And Equipment NonCashPurchaseOfPropertyPlantAndEquipment	764000
CY2016	orgo	Non Cash Purchase Of Property Plant And Equipment NonCashPurchaseOfPropertyPlantAndEquipment	63000
CY2017	orgo	Non Cash Extinguishment Of Subordinated Notes Of Affiliates NonCashExtinguishmentOfSubordinatedNotesOfAffiliates	-4577000
CY2017	orgo	Non Cash Accretion Of Redeemable Common Stock NonCashAccretionOfRedeemableCommonStock	-423000
CY2017	us-gaap	Stock Issued1 StockIssued1	16609000
CY2017	orgo	Non Cash Deconsolidation Of Variable Interest Entities NonCashDeconsolidationOfVariableInterestEntities	-9052000
CY2017	orgo	Issue Of Deferrd Acquisition Consideration IssueOfDeferrdAcquisitionConsideration	-7500000
CY2018Q4	us-gaap	Debt Instrument Collateral Amount DebtInstrumentCollateralAmount	4448000
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0
CY2018	orgo	Proceeds From Affiliates Long Term Debt ProceedsFromAffiliatesLongTermDebt	15000000
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66670850
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Entity Registrant Name EntityRegistrantName	Organogenesis Holdings Inc.
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001661181
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	310930000
CY2018	dei	Trading Symbol TradingSymbol	ORGO
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	92009737
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="color: rgb(0, 0, 0); font-family: "times new roman"; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; margin-right: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Reclassification of Prior Period Balances</div></div></div><div style="color: rgb(0, 0, 0); font-family: "times new roman"; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; margin-right: 0px;">Reclassifications have been made to prior period amounts to conform to the current-year presentation of the reporting of deferred principal payments on outstanding capital lease obligations as a component of the current portion of capital lease obligations on the consolidated balance sheets. These amounts were previously reported as accrued expenses on the consolidated balance sheets. These reclassifications have no effect on the reported net loss or net equity for the years ended December 31, 2018, 2017 and 2016.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001193125-19-078332-index-headers.html	Edgar Link	pending
0001193125-19-078332-index.html	Edgar Link	pending
0001193125-19-078332.txt	Edgar Link	pending
0001193125-19-078332-xbrl.zip	Edgar Link	pending
d716594d10k.htm	Edgar Link	pending
d716594dex1037.htm	Edgar Link	pending
d716594dex211.htm	Edgar Link	pending
d716594dex231.htm	Edgar Link	pending
d716594dex311.htm	Edgar Link	pending
d716594dex312.htm	Edgar Link	pending
d716594dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g716594g19t78.jpg	Edgar Link	pending
g716594g25g98.jpg	Edgar Link	pending
g716594g29p06.jpg	Edgar Link	pending
g716594g33m31.jpg	Edgar Link	pending
g716594g37n06.jpg	Edgar Link	pending
g716594g37z44.jpg	Edgar Link	pending
g716594g42m94.jpg	Edgar Link	pending
g716594g43x40.jpg	Edgar Link	pending
g716594g48e36.jpg	Edgar Link	pending
g716594g50p21.jpg	Edgar Link	pending
g716594g52m02.jpg	Edgar Link	pending
g716594g54x25.jpg	Edgar Link	pending
g716594g56b91.jpg	Edgar Link	pending
g716594g75y16.jpg	Edgar Link	pending
g716594g86w29.jpg	Edgar Link	pending
g716594g93a54.jpg	Edgar Link	pending
orgo-20181231.xml	Edgar Link	completed
orgo-20181231.xsd	Edgar Link	pending
orgo-20181231_cal.xml	Edgar Link	unprocessable
orgo-20181231_def.xml	Edgar Link	unprocessable
orgo-20181231_lab.xml	Edgar Link	unprocessable
orgo-20181231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORGO
Organogenesis Holdings Inc. Stock $orgo

2019 Q1 Form 10-K Financial Statement

#000119312519078332 Filed on March 18, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORGO Organogenesis Holdings Inc. Stock $orgo

2019 Q1 Form 10-K Financial Statement

#000119312519078332 Filed on March 18, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORGO
Organogenesis Holdings Inc. Stock $orgo